Kornimate/medical-research-clean huggingface dataset:
aging and marijuana: benefits, effects, and risks

Conditions: Cannabis Use

Summary: investigators will gather data on both the beneficial and harmful effects of edible cannabis of varying composition (thc-only vs. cbd-only vs. thc+cbd), and will examine the process by which older adult cannabis users decide what type of cannabis product is preferred.

older adults are currently the fastest growing group of cannabis users in the u.s, and are more likely to use cannabis for medicinal purposes (e.g., pain, trouble sleeping, depression/anxiety) than for recreational purposes, despite having little data to guide their decisions about what type of product to use. this project utilizes a patient-centered observational design to recruit and assess older adults who are interested in using cannabis compared to a control group who is not interested in cannabis use. investigators will gather data on both the beneficial and harmful effects of edible cannabis of varying composition (thc-only vs. cbd-only vs. thc+cbd), and will examine the process by which older adult cannabis users decide what type of cannabis product is preferred.

Eligibility criteria:
inclusion criteria: * at least 60 years of age * able to provide informed consent * cannabis users: must not currently use cannabis more than 7 times per month and not for pain, sleep, depression or anxiety in the past 6 months * cannabis non-users: should not have used cannabis in the past year and have not used regularly (e.g., more than weekly) for more than one year in the past 20 years * cannabis users: must be interested in using cannabis for at least one of the following complains: pain, sleep problems, depression, anxiety * non-users: must not be interested in using cannabis but have at least one of the following complaints: pain, sleep problems, depression, anxiety * cannabis users: must be comfortable using edible cannabis and having a mobile laboratory (dodge van) parked at their home * female participants must be postmenopausal * comfortable reading and writing in english * planning to stay in the boulder/denver area for the next month * must be comfortable with blood draws exclusion criteria: * blood alcohol level \> 0 at screening (to sign consent form) * report of other drug use (cocaine, opiates, methamphetamine) in the past 90 days or fail urine screen for any of these drugs * past or current diagnosis of psychosis * current use of antipsychotic medications * heavy drinking; alcohol use disorder identification test (audit) test score \>8 * inability/discomfort/unwillingness with getting in and out of the mobile laboratory van * history of vertigo or falls within the past six months
validation of a scale of self-assessment of fear faces in children 4 to 12 years

Conditions: Fear

Summary: since the 2000s, the experiences of children and especially their fear during a consultation, a treatment or examination is food for thought in our establishment. there is no tool validated self-assessment of fear to 6 faces. it therefore appeared necessary to us to create this tool. the scale self-assessment of the fear that we have developed consists of six faces representing a gradual level of fear: the child can easily describe their level of fear, which allows for appropriate care.


Eligibility criteria:
inclusion criteria: * children aged 4 to 12 years. * enrolled in one of the participating institutions in the study (steps 1-5) or consultant pediatric emergencies at the children of limoges (step 6). * authorization of at least one person having parental authority for the child to participate in the study. * children affiliates or benefiting from a social security exclusion criteria: * children with psychomotor disorders that prevent the use of the scale studied and understanding instructions. * children in vital emergency

Keywords: scary scale
effect of telephone-supported joint protection technique training

Conditions: Woman; Epicondylitis

Summary: there is limited evidence of the efficacy of joint protection principles in individuals diagnosed with lateral epicondylitis in the literature. the aim of this study was to investigate the effect of training of the telephone supported joint protection technique education on pain and upper extremity function in individuals with lateral epicondylitis. new information will be obtained according to the results.

there is limited evidence of the efficacy of joint protection principles in individuals diagnosed with lateral epicondylitis in the literature. the aim of this study was to investigate the effect of training of the telephone supported joint protection technique education on pain and upper extremity function in individuals with lateral epicondylitis. new information will be obtained according to the results.

Eligibility criteria:
* unilateral lateral epicondylitis diagnosis * individuals between 18-40 exclusion criteria: -individuals with a history of surgery
side population in pancreatic ductal adenocarcinoma (pdac)

Conditions: Neoplasm; Pancreas

Summary: in the current project we aim to study the oncological process of pancreatic cancer, from a perspective of the csc-theory and in particular through the 'side population' (sp)-approach. the sp seems to be enriched for csc and doesn't a priori exclude any csc-subpopulation. after isolation from pancreatic cancer resection specimens, sp cells will be characterized by gene-expression profiling based on microarray analysis. we'll identify markers and pathways (with emphasis for stem cell and cancer -related ones) that are differentially expressed in sp versus the rest of tumour cells (the 'main population' or mp). in order to assess the prognostic relevance of the sp, we'll study these genes using the high-throughput nanostring technology in about 200 snap-frozen pdac resection specimens of patients from our prospective database. finally, two monoclonal antibodies (mab) will be tested as novel therapeutic agents in vivo (mouse model), wherein the choice of mab will be based on prognostically relevant molecular targets and pathways obtained from the nanostring results.


Eligibility criteria:
inclusion criteria: * resected pancreatic ductal adenocarcinoma (pdac) * informed consent exclusion criteria: * age \< 18years * pregnancy * pre-operative radiotherapy * pre-operative chemotherapy * ipmt

Keywords: pancreas cancer stem cell
a comparison of fluconazole and ketoconazole in the treatment of fungal infections of the throat in patients with weakened immune systems

Conditions: Candidiasis, Esophageal; HIV Infections

Summary: to compare the safety, tolerance, and effectiveness of fluconazole and ketoconazole in the treatment of candidal esophagitis in immunocompromised patients.


Eligibility criteria:
inclusion criteria prior medication: allowed: * cyclosporin if levels can be monitored for proper cyclosporin dose adjustment. exclusion criteria co-existing condition: patients with the following are excluded: * evidence of noncandidal systemic fungal infections. * leukopenia (white blood cell count less than 1000/mm3), or expected to develop leukopenia during the study. * other condition known to be associated with poor ketoconazole absorption, e.g., hypochlorhydria. * leukemia requiring chemotherapy. * any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment. concurrent medication: excluded: * warfarin. * immunostimulants. * interferon. * oral or topical antifungal agents. concurrent treatment: excluded: * lymphocyte replacement. patients with the following are excluded: * history of allergy to imidazoles. * abnormalities which may preclude esophagoscopy or endoscopy before or during the study. * inability to tolerate fluconazole or ketoconazole. * inability or unwillingness to give written informed consent. * life expectancy \< 2 months. prior medication: excluded: * rifampin or ansamycin, pending clarification of drug interactions between these drugs and fluconazole. * warfarin. patients must meet the cdc criteria for the diagnosis of aids or be otherwise immunocompromised (e.g., malignancy, renal transplant) and have a diagnosis of oral candidiasis and/or esophageal symptoms of dysphagia and/or odynophagia. illicit or illegal drug use.

Keywords: aids-related opportunistic infections immune tolerance ketoconazole esophagitis fluconazole acquired immunodeficiency syndrome candidiasis, oral
the effect of diabetes mellitus on the prognosis of patients with covid-19

Conditions: Covid19; Diabetes Mellitus

Summary: all hospitalised patients with covid-19 who have positive rt-pcr for sars-cov-2 will be included in the study. the patients will be divided into two groups, as diabetics and non-diabetics. the covid-19 patients' medical records will be evaluated and compared in terms of the duration of hospitalization, the presence of lung involvement in computerised tomography, the need for intensive care unit and mortality rates in patients with and without diabetes.

all hospitalised patients with covid-19 who have positive rt-pcr for sars-cov-2 will be included in the study. the patients will be divided into two groups, as diabetics and non-diabetics. the diagnosis of diabetes mellitus will be extracted from the medical records and medical history of the patients hospitalised with covid-19. the covid-19 patients medical records will be evaluated and compared in terms of the duration of hospitalization, the presence of lung involvement in computerised tomography, the need for intensive care unit and mortality rates in patients with and without diabetes.

Eligibility criteria:
inclusion criteria: * patients hospitalized for covid-19 exclusion criteria: * patients with known malignancy * pregnant patients
study designed to clinically evaluate sinus wash device prototypes

Conditions: Sinusitis; Maxillary Sinusitis

Summary: the purpose of this study is to clinically evaluate sinus wash device prototypes in patients with sinusitis during endoscopic sinus surgery (ess) and in the hospital outpatient


Eligibility criteria:
inclusion criteria: 1. male or female, 18-65 years of age. 2. signs and symptoms of acute exacerbation during chronic maxillary sinusitis. 3. pain higher than 5 in vas of 0-10. 4. able to understand and provide written informed consent. exclusion criteria: 1. patients who have a clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation as determined by medical history based on the opinion of the investigator. 2. extensive sinonasal polyps that may interfere with the treatment procedure. 3. previous sinonasal surgery. 4. acute exacerbation of sinusitis in the frontal or sphenoid sinuses. 5. sinonasal osteoneogenesis. 6. cystic fibrosis. 7. sinonasal tumors or obstructive lesions. 8. presence of features consistent with sinus fungal disease on ct or physical examination. 9. history of facial trauma that distorted the sinus anatomy. 10. ciliary dysfunction. 11. history of insulin dependent diabetes. 12. not able to stop anti-coagulant (e.g., warfarin) until the international normalized ratio (inr) is below 1.5. 13. not able to stop anti-platelet (e.g., clopidogrel, aspirin, etc.) for at least 14 days prior to study procedure. 14. not able to stop any non-steroidal anti-inflammatory medications and homeopathic medications for at least 14 days prior to the study procedure. 15. pregnancy. 16. psychiatric disease. 17. currently participating in other drug or device studies. 18. investigator's opinion that the subject should not be in the study such as any conditions that could compromise the wellbeing of the patient or integrity of the study or prevent the patient from meeting or performing study requirements. 19. patient is not capable of following the study schedule for any reason.

Keywords: sinus wash sinus lavage sinusitis
the papillary muscle approximation provide stability of mitral valve repair for ischemic mitral regurgitation

Conditions: Mitral Regurgitation

Summary: recent publications show that an adjunctive subvalvular repair during mitral annuloplasty for secondary mitral regurgitation effective in preventing recurrent regurgitation. one of these procedures is the papillary muscles approximation. however, the safety and the positive impact of this method are still in doubt.

ischemic mitral regurgitation develops in 10-50% of patients after myocardial infarction. among several surgical procedures, mitral ring annuloplasty has been the method of choice for a considerable period. however, mitral regurgitation recurrence after surgery has a reported occurrence that ranges from 5% to 58%. careful consideration of the mechanisms underlying recurrence of mitral regurgitation after annuloplasty might explain the unsatisfactory outcomes. the pathophysiology of imr is complex and results from the imbalance between closing and tethering forces acting on the mitral valve. enlargement of the left ventricular chamber, and displacement of papillary muscles in apical and lateral direction increase the tethering forces. left ventricular and papillary muscle dyssynchrony, reduced myocardial contractility decrease closing forces, which lead to impaired leaflet coaptation and appearance of mitral regurgitation. thus, treatment of mitral insufficiency requires an integrated approach affecting all units of the pathogenesis of mr recurrence. recent publications show that an adjunctive subvalvular repair during mitral annuloplasty for secondary mitral regurgitation effective in preventing recurrent regurgitation. one of these procedures is the papillary muscles approximation. however, the safety and the positive impact of this method are still in doubt. this study is conducted to identify the positive qualities and safety of this technique.

Eligibility criteria:
inclusion criteria: * ischemic cardiomyopathy, * ischemic mitral regurgitation. exclusion criteria: * degenerative mitral valve disease, * unstable angina, * recent myocardial infarction (\< 6 months), * papillary muscles rupture, * severe right ventricular dysfunction, * multiple organ failures, * concomitant left ventricular reconstruction, * aortic valve procedures.

Keywords: papillary muscles approximation
a two part trial investigating nn1952 in healthy subjects and subjects with type 1 and type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Healthy

Summary: this trial is conducted in europe. the aim of this trial is to investigate the safety, tolerance, pharmacokinetics (exposure of drug) and pharmacodynamics (effect) of nn1952 as tablets in healthy volunteers and subjects with type 1 and type 2 diabetes. the trial consists of two parts. in part 1, single escalating doses of nn1952, placebo or insulin aspart will be given to healthy volunteers. in part 2, subjects with type 1 or type 2 diabetes will receive single doses of nn1952 (with/without a meal), insulin aspart and placebo.


Eligibility criteria:
inclusion criteria: * for trial part 1, the following applies: * gender: male * age: 18-55 years * bmi (body mass index): 18-28 kg/m2 * study participants considered to be healthy * for trial part 2, the following applies: * gender: male or female of no childbearing potential * age: 18-65 years * type 1 diabetes: bmi (body mass index): 18-28 kg/m2 * type 2 diabetes: bmi (body mass index): 22-35 kg/m2 * type 1 or type 2 diabetes for at least 12 months * type 1 diabetes: treatment with insulin for at least 12 months * type 2 diabetes: treatment with insulin for at least 3 months exclusion criteria: * known or suspected allergy to the trial product or related products * presence of illness or infection that may confound the results of the study or pose a risk to the study participant by dosing nn1952, as judged by the investigator * presence of acute gastrointestinal symptoms (for example nausea, vomiting, heartburn or diarrhoea)
empirical mode decomposition and decision tree in sarcopenia

Conditions: Sarcopenia; Fall; Gait, Unsteady; Balance; Distorted

Summary: sarcopenia is quickly becoming a major global public health issue. falls are the leading cause of mortality among the elderly, and they must be addressed. the investigators will use machine learning techniques such as empirical mode decomposition technology and decision tree algorithms to extract the characteristics and classification of sarcopenia in this retrospective study in order to offer clinically proven and effective interventional strategies to prevent, stabilize, and reverse sarcopenia.

sarcopenia is becoming a severe global public health concern as the world's elderly population grows. sarcopenia is characterized by muscular mass and strength loss, as well as impaired physical performance, and it is frequently connected with negative health outcomes such as falls. falls are a primary cause of death in older individuals and must be addressed. sarcopenia is currently diagnosed clinically using three primary technologies: imaging technology, precision medicine, and machine learning. in this study, the investigators will use previously collected data from nearly 200 community-dwelling subjects, including medical history, biochemistry, body composition, balance and gait, electromyography, and functional performance, to extract the characteristics and classification of sarcopenia using machine learning techniques such as empirical mode decomposition technology and decision tree algorithms. the investigators intend to offer clinically proven and effective interventional strategies to prevent, stabilize, and reverse sarcopenia.

Eligibility criteria:
inclusion criteria: * aged from 40 - 90 * dxa test performed * blood sample tests were performed exclusion criteria: * stroke history * amputation * cancer related disease

Keywords: empirical mode decomposition machine learning decision tree
adaptive virtual consultation tool to enhance education and understanding in patients with prostate cancer

Conditions: Prostate Carcinoma

Summary: this clinical trial aims to design and validate an adaptive virtual consultation tool (avct) for men with prostate cancer (pc). an avct utilizes health literacy assessments in combination with learning preferences and individual disease characteristics to provide focused and guided knowledge on pc tailored to the individual patient. using an avct to enhance patient education may improve patient understanding and result in higher patient satisfaction with treatment decisions amongst men with pc.

primary objectives: i. to develop an adaptive virtual consultation tool for pc (avct): ia. to incorporate and integrate the inputs from a diverse group of patients (including minorities), patient advocates, nursing, physicians and education experts in the design process for the adaptive consultation tool; ib. employ user centered iterative design approach to develop an adaptive learning tool on mobile devices that is tailored to individuals based on symptoms, health literacy, learning style, and disease specific characteristics. ii. to assess the feasibility, acceptability and usability of avct: iia. to validate the design approach and customization rules at the completion of the participatory design process using a convenience sample of subjects through assessment of system interaction logs and qualitative feedback from users on cognition, ease-of-use, usability and customization efficacy; iib. to utilize the feasibility study results in (2a) to refine the interface, information presentation, and adaptive customization approach. iii. to determine the efficacy of avct using a small-scale comparative study: iiia. to design and execute a three arm comparative study consisting of adaptive virtual consultation, non-adaptive virtual consultation and standard-practice information-only control intervention and assess the comparative efficacy of the tool on the main outcome variable, satisfaction with health care episode; iiib. to measure changes in other outcome variables at baseline, post-intervention, 3-month and 12-month duration; iiic. to analyze the mediating influence of decision self-efficacy and a number of moderating factors including preference for decision-making participation and health literacy on outcome variables. outline: patients are randomized to 1 of 3 arms. arm 1: patients participate in an adaptive virtual consultation on trial. arm 2: patients participate in a non-adaptive virtual consultation on trial. arm 3: patients receive information-only on trial. after completion of study intervention, patients are followed up at 3- and 12-months post treatment decision.

Eligibility criteria:
inclusion criteria: * the participants in this study will be community dwelling, males with prostate cancer (pc) and their healthcare advocate, if applicable * proficiency in english is required exclusion criteria: * mental incompetency to participate in the study and/or no treatment option due to other health reasons
a phase ii study of mdx-060 in subjects with relapsed or refractory hodgkin's disease

Conditions: Hodgkin's Disease

Summary: this study is designed to determine the objective response rate in patients with relapsed or refractory hodgkin's disease treated with mdx-060 in combination with gemcitabine or gemcitabine alone.

secondary objectives include: * to characterize progression-free survival * to characterize time to progression * to determine response duration * to characterize the effect of study drug on health-related quality of life * to explore the correlation of positron emission tomography (pet) scan results with objective responses observed with conventional imaging in this patient population * to characterize the immunogenicity response of mdx-060 * to characterize the safety of mdx-060, and * to characterize the pharmacokinetic profile of mdx-060

Eligibility criteria:
inclusion criteria: * diagnosis of hodgkin's disease \[hd\] (excluding hiv-associated hd) * patients must have read, understood, and provided written informed consent and health insurance portability and accountability act (hipaa) authorization after the nature of the study has been fully explained * patients must have failed or relapsed following second line (i.e., salvage) chemotherapy or relapsed or failed following autologous stem cell transplant * ecog performance status of 0-2 * patients must have bi-measurable disease * at least 4 weeks since the last chemotherapy or radiation therapy with clinical evidence of recovery from any toxicity associated with such treatment * life expectancy 12 weeks or greater * screening laboratory values must be met * patients on corticosteroids must be tapered off the medication 2 weeks prior to study drug administration and remain off corticosteroids until study completion. exclusion criteria: * previous treatment with any anti-cd30 antibody * history of allogeneic transplant * any tumor lesion 10cm or greater in diameter * any other malignancy, excluding basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ. any cancer from which the patient has been disease free for at least 5 years is permissible. * any significant active or chronic infection * apparent active or latent tuberculosis (tb) infection * patients who are pregnant or nursing * any underlying medical condition which, in the investigator's opinion, will make the administration of the study drug hazardous or obscure the interpretation of adverse events * concomitant chemotherapy, steroids, investigational agents, other anti-hd biologics, or radiation therapy

Keywords: relapsed or refractory hodgkin's disease